The liver disease market growth is driven by increasing prevalence of liver disorders, including non-alcoholic fatty liver disease (NAFLD), hepatitis B and C, alcoholic liver disease, liver fibrosis, and cirrhosis, is driving unprecedented demand for innovative therapies, advanced diagnostics, and precision care solutions. The liver disease market is projected to reach USD 18.6 billion by 2024, supported by increasing clinical awareness, government healthcare initiatives, and public-private partnerships. North America dominated the liver disease market by advanced liver disease therapeutics and AI-enabled diagnostic solutions, while Asia-Pacific demonstrates rapid growth due to expanding diagnostic infrastructure, rising patient populations, and supportive healthcare policies. Europe continues steady growth driven by reimbursement support, early detection programs, and advanced treatment accessibility.
Liver Disease overview
Published by MMR Statistics Research Team, Updated